查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2026915

內分泌檢測市場預測至2034年－按檢測類型、技術、最終用戶和地區分類的全球分析

Endocrine Testing Market Forecasts to 2034 - Global Analysis By Test Type (Human Chorionic Gonadotropin Hormone Test, Prolactin Test, Progesterone Test and Other Test Types), Technology, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球內分泌檢測市場規模將達到 38 億美元，並在預測期內以 10.4% 的複合年成長率成長，到 2034 年將達到 83 億美元。

內分泌檢測評估人體內分泌系統中的荷爾蒙水平，該系統調節多種生理功能。透過測量血液、尿液或唾液樣本中的荷爾蒙濃度，這種診斷方法有助於識別荷爾蒙失衡或失調。甲狀腺激素、皮質醇、胰島素以及睪固酮和雌激素等生殖激素都是常見的檢測荷爾蒙。

根據世界衛生組織 (WHO) 2022 年 3 月的報告，全球有 6.5 億肥胖成年人、3.4 億青少年和 3,900 萬名肥胖兒童，而且這些數字還在持續上升。

生活方式相關疾病增加

內分泌相關疾病的增加部分歸因於生活方式的改變，例如久坐不動的生活方式和不健康的飲食習慣。因此，人們越來越需要能夠準確識別荷爾蒙失衡並實現這些疾病早期診斷的檢測方法。此外，隨著醫療專業人員尋求最先進的設備來應對診斷文明病的挑戰，準確及時的荷爾蒙評估對於有效治療的重要性日益凸顯，內分泌檢測市場預計將會成長。

檢體採集錯誤

正確的檢體採集、儲存和運輸對於確保荷爾蒙濃度測量的準確性至關重要。檢體處理不當、污染和運輸延誤等問題會損害檢體完整性，導致檢測結果不準確。此外，不同醫療機構資料收集方法的不一致也會造成結果差異。然而，解決這些與檢體相關的問題對於維持內分泌檢測的準確性和一致性至關重要，這也凸顯了製定標準化流程和加強醫護人員訓練的必要性。

伴隨診斷

伴隨診斷為內分泌檢測市場創造了獨特的機遇，它為內分泌疾病的個人化治療提供了個人化解決方案。透過識別特定的生物標記和遺傳標記物，這些診斷方法能夠幫助醫療專業人員為患者配對最合適的治療方法。這種精準的方法能夠最大限度地減少副作用，提高治療效果，並改善內分泌檢測的治療結果。此外，這種個人化方法不僅能夠提升患者照護，還有助於提高內分泌相關醫療保健的整體效率和成本效益。

與智慧財產權相關的挑戰

智慧財產權問題源自於新型檢測、生物標記和診斷技術的研發和應用。投資研發的公司必須專注於專利侵權問題，因為競爭對手可能會試圖模仿或改進其獨特的檢測方法。內分泌診斷的動態特性引發了關於現有專利範圍和合法性的疑問，進而導致智慧財產權糾紛。

新冠疫情的影響：

新冠疫情對內分泌檢測市場產生了顯著影響。由於內分泌系統是該病毒可影響的器官之一，因此對內分泌檢測的需求激增，以評估感染者的荷爾蒙失衡和併發症。為了了解病毒對荷爾蒙水平的影響，人們迫切需要全面的診斷解決方案，這促使內分泌檢測產業創新和研究蓬勃發展。儘管醫療系統受到衝擊，但對內分泌疾病診斷和治療的重視使得內分泌檢測市場在充滿挑戰的時期仍保持成長。

在預測期內，免疫檢測領域預計將成為最大的細分市場。

由於免疫檢測領域實現了顯著成長。內分泌疾病（包括糖尿病和甲狀腺疾病）發生率的上升，推動了對準確有效診斷技術的需求。此外，自動化、新檢測法的開發以及技術的進步也促進了該領域的成長。

在預測期內，胰島素檢測細分市場預計將呈現最高的複合年成長率。

預計在預測期內，胰島素檢測領域將呈現最高的複合年成長率。由於糖尿病管理高度依賴胰島素水平監測，因此對胰島素檢測的需求旺盛。檢測技術的進步，例如更快、更準確的檢測方法，也推動了該領域的成長。此外，人們對個人化醫療和糖尿病早期檢測的日益關注也促進了胰島素檢測的普及。

市佔率最大的地區：

由於內分泌疾病盛行率不斷上升、人們對荷爾蒙健康的認知不斷提高以及醫療基礎設施的進步，亞太地區佔據了最大的市場佔有率。最新診斷技術的引入和醫療設施的擴建也推動了市場的成長趨勢。此外，研發投入的增加以及政府的積極舉措，進一步促進了市場成長。

複合年成長率最高的地區：

北美市場正經歷強勁成長，這主要得益於內分泌疾病發病率的上升以及公眾對早期疾病檢測重要性的認知不斷提高。該地區高昂的醫療費用支出和完善的醫療基礎設施也進一步支撐了市場成長。此外，生物技術和製藥行業研發投入的增加正在推動內分泌檢測技術的創新，從而進一步加速區域成長。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域分類
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對重點公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 技術分析
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章 全球內分泌檢測市場：依檢測類型分類

  • 人類絨毛膜促性腺激素分泌(hCG) 檢測
  • 催乳素試驗
  • 孕酮測試
  • 胰島素測試
  • 甲狀腺刺激素試驗
  • 黃體激素試驗
  • 脫氫表雄酮硫酸酯試驗
  • 雌二醇試驗
  • 皮質醇測試
  • 睪酮檢測
  • 濾泡刺激素試驗
  • 其他測試類型

第6章 全球內分泌檢測市場：依技術分類

  • 基於核酸
  • 質譜分析
  • 層析法
  • 免疫檢測
  • 其他技術

第7章 全球內分泌檢測市場：依最終用戶分類

  • 臨床檢查室
  • 診斷中心
  • 醫院
  • 其他最終用戶

第8章 全球內分泌檢測市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第9章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第10章：公司簡介

  • AB Sciex
  • Abbott Laboratories
  • Agilent Technologies Inc.
  • Beckman Coulter, Inc.
  • Biomedical Technologies Limited
  • BioMerieux SA
  • Bio Rad Laboratories, Inc.
  • Danaher Corporation
  • DH Tech. Dev. Pte. Ltd.
  • DiaSorin SpA
  • F. Hoffmann-La Roche Ltd
  • Hologic Inc.
  • Laboratory Corporation of America Holdings
  • Ortho Clinical Diagnostics
  • Qiagen NV
  • Quest Diagnostics
  • Siemens Healthineers AG
  • Thermo Fisher Scientific
Product Code: SMRC24723

According to Stratistics MRC, the Global Endocrine Testing Market is accounted for $3.8 billion in 2026 and is expected to reach $8.3 billion by 2034 growing at a CAGR of 10.4% during the forecast period. Endocrine testing involves the assessment of hormone levels in the body's endocrine system, which regulates various physiological functions. By determining the hormone concentrations in blood, urine, or saliva samples, this diagnostic procedure aids in the identification of hormonal imbalances or disorders. Thyroid hormones, cortisol, insulin, and reproductive hormones like testosterone and estrogen are among the hormones that are frequently tested.

According to the World Health Organization (WHO) in March 2022, 650 million adults, 340 million teenagers, and 39 million children are obese around the world and the number is still rising.

Market Dynamics:

Driver:

Rise in disorders associated with lifestyle

The increase in the endocrine related disorders is partly attributed to alterations in lifestyle patterns, like sedentary lifestyle and unhealthy eating habits. The need for diagnostic tests that can precisely identify hormonal imbalances and offer early diagnosis of such conditions has increased. Additionally, the market for endocrine testing is expected to grow as medical professionals look for cutting-edge instruments to handle the difficulties in diagnosing lifestyle-related illnesses, stressing the need for accurate and timely hormone evaluations for efficient illness treatment.

Restraint:

Errors in specimen collection

Appropriate specimen collection, storage, and transportation are critical to guaranteeing accurate hormone level measurements. Problems like incorrect sample handling, contamination, or transportation delays can damage the samples' integrity and produce inaccurate test results. Variability in outcomes may also be caused by different healthcare settings using inconsistent methods for data collection. However, it is imperative that these sample-related issues are resolved in order to preserve the accuracy and consistency of endocrine tests, underscoring the necessity of uniform procedures and training for healthcare personnel.

Opportunity:

Companion diagnostics

Companion diagnostics present a unique opportunity in the endocrine testing market by offering tailored solutions for personalized treatment in endocrine disorders. By identifying particular biomarkers or genetic markers, these diagnostics assist medical professionals in matching patients with the most appropriate treatments. This precision approach minimizes side effects, maximizes therapeutic interventions, and improves treatment outcomes in endocrine testing. Moreover, this customized approach enhances patient care while also adding to the general efficacy and affordability of endocrine-related healthcare.

Threat:

Intellectual property challenges

Intellectual property issues are brought about by the creation and application of novel testing techniques, biomarkers, and diagnostic technologies. Businesses that spend money on R&D have to worry about patent infringement because rivals might try to copy or enhance proprietary testing methods. The dynamic nature of endocrine diagnostics gives rise to inquiries concerning the extent and legitimacy of existing patents, thereby engendering conflicts concerning intellectual property rights.

Covid-19 Impact:

The endocrine testing market has been greatly affected by the COVID-19 pandemic. The endocrine system is one of the organs that the virus can affect, so there is a greater need for endocrine tests to evaluate hormonal imbalances and complications in infected individuals. The endocrine testing industry has seen a surge in innovation and research due to the need for comprehensive diagnostic solutions to comprehend the virus's impact on hormone levels. The focus on diagnosing and treating endocrine disorders has kept the endocrine testing market growing during these difficult times, despite disruptions in the healthcare system.

The immunoassay segment is expected to be the largest during the forecast period

The immunoassay segment has grown substantially because of its high sensitivity and specificity in identifying hormones and associated biomarkers. The need for precise and effective diagnostic techniques has been fueled by the rising incidence of endocrine disorders, including diabetes and thyroid issues. Furthermore, automation, the creation of new assays, and technological developments has all contributed to this segment's growth.

The insulin test segment is expected to have the highest CAGR during the forecast period

Insulin test segment is expected to have the highest CAGR during the forecast period. Insulin tests are in high demand because diabetes management greatly depends on insulin level monitoring. The sector's growth has also been aided by developments in testing technologies, such as faster and more accurate assays. Insulin test adoption has also been influenced by the growing emphasis on personalized medicine and the early detection of diabetes.

Region with largest share:

Asia Pacific region dominated the largest share due to the increasing prevalence of endocrine disorders, rising awareness about hormonal health, and advancements in healthcare infrastructure. The adoption of modern diagnostic technologies and the expansion of healthcare facilities contribute to the market's upward trajectory. Additionally, heightened investments in research and development, coupled with proactive government initiatives, further fuel the market's expansion.

Region with highest CAGR:

The market has grown profitably in North America due to rising incidence of endocrine disorders and increased public awareness of early disease detection. The region's high healthcare spending and well-established healthcare infrastructure have further stimulated market growth. Furthermore, increased R&D spending in the biotechnology and pharmaceutical industries has sparked innovation in endocrine testing techniques, which has further fuelled the regional growth.

Key players in the market

Some of the key players in Endocrine Testing market include AB Sciex, Abbott Laboratories, Agilent Technologies Inc., Beckman Coulter, Inc., Biomedical Technologies Limited, BioMerieux SA, Bio Rad Laboratories, Inc. , Danaher Corporation, DH Tech. Dev. Pte. Ltd., DiaSorin SpA, F. Hoffmann-La Roche Ltd, Hologic Inc., Laboratory Corporation of America Holdings, Ortho Clinical Diagnostics, Qiagen N.V., Quest Diagnostics, Siemens Healthineers AG and Thermo Fisher Scientific.

Key Developments:

In December 2023, Roche announced the entry into a definitive merger agreement to acquire Carmot Therapeutics, Inc, a privately owned US company based in Berkeley, California. Carmot's R&D portfolio includes clinical stage subcutaneous and oral incretins with best-in-class potential to treat obesity in patients with and without diabetes, as well as a number of preclinical programs.

In May 2023, Hologic Inc., a global leader in women's health, announced a partnership with recently drafted NFL cornerback Kelee Ringo and his mother, breast cancer survivor Tralee Hale, to educate women on the importance of prioritizing annual mammograms and other key health screenings.

Test Types Covered:

  • Human Chorionic Gonadotropin Hormone Test
  • Prolactin Test
  • Progesterone Test
  • Insulin Test
  • Thyroid Stimulating Hormone Test
  • Luteinizing Hormone Test
  • Dehydroepiandrosterone Sulfate Test
  • Estradiol Test
  • Cortisol Test
  • Testosterone Test
  • Follicle Stimulating Hormone Test
  • Other Test Types

Technologies Covered:

  • Nucleic Acid Based
  • Mass Spectroscopy
  • Chromatography
  • Immunoassay
  • Other Technologies

End Users Covered:

  • Clinical Laboratories
  • Diagnostic Centers
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Endocrine Testing Market, By Test Type

  • 5.1 Introduction
  • 5.2 Human Chorionic Gonadotropin Hormone Test
  • 5.3 Prolactin Test
  • 5.4 Progesterone Test
  • 5.5 Insulin Test
  • 5.6 Thyroid Stimulating Hormone Test
  • 5.7 Luteinizing Hormone Test
  • 5.8 Dehydroepiandrosterone Sulfate Test
  • 5.9 Estradiol Test
  • 5.10 Cortisol Test
  • 5.11 Testosterone Test
  • 5.12 Follicle Stimulating Hormone Test
  • 5.13 Other Test Types

6 Global Endocrine Testing Market, By Technology

  • 6.1 Introduction
  • 6.2 Nucleic Acid Based
  • 6.3 Mass Spectroscopy
  • 6.4 Chromatography
  • 6.5 Immunoassay
  • 6.6 Other Technologies

7 Global Endocrine Testing Market, By End User

  • 7.1 Introduction
  • 7.2 Clinical Laboratories
  • 7.3 Diagnostic Centers
  • 7.4 Hospitals
  • 7.5 Other End Users

8 Global Endocrine Testing Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 AB Sciex
  • 10.2 Abbott Laboratories
  • 10.3 Agilent Technologies Inc.
  • 10.4 Beckman Coulter, Inc.
  • 10.5 Biomedical Technologies Limited
  • 10.6 BioMerieux SA
  • 10.7 Bio Rad Laboratories, Inc.
  • 10.8 Danaher Corporation
  • 10.9 DH Tech. Dev. Pte. Ltd.
  • 10.10 DiaSorin SpA
  • 10.11 F. Hoffmann-La Roche Ltd
  • 10.12 Hologic Inc.
  • 10.13 Laboratory Corporation of America Holdings
  • 10.14 Ortho Clinical Diagnostics
  • 10.15 Qiagen N.V.
  • 10.16 Quest Diagnostics
  • 10.17 Siemens Healthineers AG
  • 10.18 Thermo Fisher Scientific

List of Tables

  • Table 1 Global Endocrine Testing Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Endocrine Testing Market Outlook, By Test Type (2023-2034) ($MN)
  • Table 3 Global Endocrine Testing Market Outlook, By Human Chorionic Gonadotropin Hormone Test (2023-2034) ($MN)
  • Table 4 Global Endocrine Testing Market Outlook, By Prolactin Test (2023-2034) ($MN)
  • Table 5 Global Endocrine Testing Market Outlook, By Progesterone Test (2023-2034) ($MN)
  • Table 6 Global Endocrine Testing Market Outlook, By Insulin Test (2023-2034) ($MN)
  • Table 7 Global Endocrine Testing Market Outlook, By Thyroid Stimulating Hormone Test (2023-2034) ($MN)
  • Table 8 Global Endocrine Testing Market Outlook, By Luteinizing Hormone Test (2023-2034) ($MN)
  • Table 9 Global Endocrine Testing Market Outlook, By Dehydroepiandrosterone Sulfate Test (2023-2034) ($MN)
  • Table 10 Global Endocrine Testing Market Outlook, By Estradiol Test (2023-2034) ($MN)
  • Table 11 Global Endocrine Testing Market Outlook, By Cortisol Test (2023-2034) ($MN)
  • Table 12 Global Endocrine Testing Market Outlook, By Testosterone Test (2023-2034) ($MN)
  • Table 13 Global Endocrine Testing Market Outlook, By Follicle Stimulating Hormone Test (2023-2034) ($MN)
  • Table 14 Global Endocrine Testing Market Outlook, By Other Test Types (2023-2034) ($MN)
  • Table 15 Global Endocrine Testing Market Outlook, By Technology (2023-2034) ($MN)
  • Table 16 Global Endocrine Testing Market Outlook, By Nucleic Acid Based (2023-2034) ($MN)
  • Table 17 Global Endocrine Testing Market Outlook, By Mass Spectroscopy (2023-2034) ($MN)
  • Table 18 Global Endocrine Testing Market Outlook, By Chromatography (2023-2034) ($MN)
  • Table 19 Global Endocrine Testing Market Outlook, By Immunoassay (2023-2034) ($MN)
  • Table 20 Global Endocrine Testing Market Outlook, By Other Technologies (2023-2034) ($MN)
  • Table 21 Global Endocrine Testing Market Outlook, By End User (2023-2034) ($MN)
  • Table 22 Global Endocrine Testing Market Outlook, By Clinical Laboratories (2023-2034) ($MN)
  • Table 23 Global Endocrine Testing Market Outlook, By Diagnostic Centers (2023-2034) ($MN)
  • Table 24 Global Endocrine Testing Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 25 Global Endocrine Testing Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 26 North America Endocrine Testing Market Outlook, By Country (2023-2034) ($MN)
  • Table 27 North America Endocrine Testing Market Outlook, By Test Type (2023-2034) ($MN)
  • Table 28 North America Endocrine Testing Market Outlook, By Human Chorionic Gonadotropin Hormone Test (2023-2034) ($MN)
  • Table 29 North America Endocrine Testing Market Outlook, By Prolactin Test (2023-2034) ($MN)
  • Table 30 North America Endocrine Testing Market Outlook, By Progesterone Test (2023-2034) ($MN)
  • Table 31 North America Endocrine Testing Market Outlook, By Insulin Test (2023-2034) ($MN)
  • Table 32 North America Endocrine Testing Market Outlook, By Thyroid Stimulating Hormone Test (2023-2034) ($MN)
  • Table 33 North America Endocrine Testing Market Outlook, By Luteinizing Hormone Test (2023-2034) ($MN)
  • Table 34 North America Endocrine Testing Market Outlook, By Dehydroepiandrosterone Sulfate Test (2023-2034) ($MN)
  • Table 35 North America Endocrine Testing Market Outlook, By Estradiol Test (2023-2034) ($MN)
  • Table 36 North America Endocrine Testing Market Outlook, By Cortisol Test (2023-2034) ($MN)
  • Table 37 North America Endocrine Testing Market Outlook, By Testosterone Test (2023-2034) ($MN)
  • Table 38 North America Endocrine Testing Market Outlook, By Follicle Stimulating Hormone Test (2023-2034) ($MN)
  • Table 39 North America Endocrine Testing Market Outlook, By Other Test Types (2023-2034) ($MN)
  • Table 40 North America Endocrine Testing Market Outlook, By Technology (2023-2034) ($MN)
  • Table 41 North America Endocrine Testing Market Outlook, By Nucleic Acid Based (2023-2034) ($MN)
  • Table 42 North America Endocrine Testing Market Outlook, By Mass Spectroscopy (2023-2034) ($MN)
  • Table 43 North America Endocrine Testing Market Outlook, By Chromatography (2023-2034) ($MN)
  • Table 44 North America Endocrine Testing Market Outlook, By Immunoassay (2023-2034) ($MN)
  • Table 45 North America Endocrine Testing Market Outlook, By Other Technologies (2023-2034) ($MN)
  • Table 46 North America Endocrine Testing Market Outlook, By End User (2023-2034) ($MN)
  • Table 47 North America Endocrine Testing Market Outlook, By Clinical Laboratories (2023-2034) ($MN)
  • Table 48 North America Endocrine Testing Market Outlook, By Diagnostic Centers (2023-2034) ($MN)
  • Table 49 North America Endocrine Testing Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 50 North America Endocrine Testing Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 51 Europe Endocrine Testing Market Outlook, By Country (2023-2034) ($MN)
  • Table 52 Europe Endocrine Testing Market Outlook, By Test Type (2023-2034) ($MN)
  • Table 53 Europe Endocrine Testing Market Outlook, By Human Chorionic Gonadotropin Hormone Test (2023-2034) ($MN)
  • Table 54 Europe Endocrine Testing Market Outlook, By Prolactin Test (2023-2034) ($MN)
  • Table 55 Europe Endocrine Testing Market Outlook, By Progesterone Test (2023-2034) ($MN)
  • Table 56 Europe Endocrine Testing Market Outlook, By Insulin Test (2023-2034) ($MN)
  • Table 57 Europe Endocrine Testing Market Outlook, By Thyroid Stimulating Hormone Test (2023-2034) ($MN)
  • Table 58 Europe Endocrine Testing Market Outlook, By Luteinizing Hormone Test (2023-2034) ($MN)
  • Table 59 Europe Endocrine Testing Market Outlook, By Dehydroepiandrosterone Sulfate Test (2023-2034) ($MN)
  • Table 60 Europe Endocrine Testing Market Outlook, By Estradiol Test (2023-2034) ($MN)
  • Table 61 Europe Endocrine Testing Market Outlook, By Cortisol Test (2023-2034) ($MN)
  • Table 62 Europe Endocrine Testing Market Outlook, By Testosterone Test (2023-2034) ($MN)
  • Table 63 Europe Endocrine Testing Market Outlook, By Follicle Stimulating Hormone Test (2023-2034) ($MN)
  • Table 64 Europe Endocrine Testing Market Outlook, By Other Test Types (2023-2034) ($MN)
  • Table 65 Europe Endocrine Testing Market Outlook, By Technology (2023-2034) ($MN)
  • Table 66 Europe Endocrine Testing Market Outlook, By Nucleic Acid Based (2023-2034) ($MN)
  • Table 67 Europe Endocrine Testing Market Outlook, By Mass Spectroscopy (2023-2034) ($MN)
  • Table 68 Europe Endocrine Testing Market Outlook, By Chromatography (2023-2034) ($MN)
  • Table 69 Europe Endocrine Testing Market Outlook, By Immunoassay (2023-2034) ($MN)
  • Table 70 Europe Endocrine Testing Market Outlook, By Other Technologies (2023-2034) ($MN)
  • Table 71 Europe Endocrine Testing Market Outlook, By End User (2023-2034) ($MN)
  • Table 72 Europe Endocrine Testing Market Outlook, By Clinical Laboratories (2023-2034) ($MN)
  • Table 73 Europe Endocrine Testing Market Outlook, By Diagnostic Centers (2023-2034) ($MN)
  • Table 74 Europe Endocrine Testing Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 75 Europe Endocrine Testing Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 76 Asia Pacific Endocrine Testing Market Outlook, By Country (2023-2034) ($MN)
  • Table 77 Asia Pacific Endocrine Testing Market Outlook, By Test Type (2023-2034) ($MN)
  • Table 78 Asia Pacific Endocrine Testing Market Outlook, By Human Chorionic Gonadotropin Hormone Test (2023-2034) ($MN)
  • Table 79 Asia Pacific Endocrine Testing Market Outlook, By Prolactin Test (2023-2034) ($MN)
  • Table 80 Asia Pacific Endocrine Testing Market Outlook, By Progesterone Test (2023-2034) ($MN)
  • Table 81 Asia Pacific Endocrine Testing Market Outlook, By Insulin Test (2023-2034) ($MN)
  • Table 82 Asia Pacific Endocrine Testing Market Outlook, By Thyroid Stimulating Hormone Test (2023-2034) ($MN)
  • Table 83 Asia Pacific Endocrine Testing Market Outlook, By Luteinizing Hormone Test (2023-2034) ($MN)
  • Table 84 Asia Pacific Endocrine Testing Market Outlook, By Dehydroepiandrosterone Sulfate Test (2023-2034) ($MN)
  • Table 85 Asia Pacific Endocrine Testing Market Outlook, By Estradiol Test (2023-2034) ($MN)
  • Table 86 Asia Pacific Endocrine Testing Market Outlook, By Cortisol Test (2023-2034) ($MN)
  • Table 87 Asia Pacific Endocrine Testing Market Outlook, By Testosterone Test (2023-2034) ($MN)
  • Table 88 Asia Pacific Endocrine Testing Market Outlook, By Follicle Stimulating Hormone Test (2023-2034) ($MN)
  • Table 89 Asia Pacific Endocrine Testing Market Outlook, By Other Test Types (2023-2034) ($MN)
  • Table 90 Asia Pacific Endocrine Testing Market Outlook, By Technology (2023-2034) ($MN)
  • Table 91 Asia Pacific Endocrine Testing Market Outlook, By Nucleic Acid Based (2023-2034) ($MN)
  • Table 92 Asia Pacific Endocrine Testing Market Outlook, By Mass Spectroscopy (2023-2034) ($MN)
  • Table 93 Asia Pacific Endocrine Testing Market Outlook, By Chromatography (2023-2034) ($MN)
  • Table 94 Asia Pacific Endocrine Testing Market Outlook, By Immunoassay (2023-2034) ($MN)
  • Table 95 Asia Pacific Endocrine Testing Market Outlook, By Other Technologies (2023-2034) ($MN)
  • Table 96 Asia Pacific Endocrine Testing Market Outlook, By End User (2023-2034) ($MN)
  • Table 97 Asia Pacific Endocrine Testing Market Outlook, By Clinical Laboratories (2023-2034) ($MN)
  • Table 98 Asia Pacific Endocrine Testing Market Outlook, By Diagnostic Centers (2023-2034) ($MN)
  • Table 99 Asia Pacific Endocrine Testing Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 100 Asia Pacific Endocrine Testing Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 101 South America Endocrine Testing Market Outlook, By Country (2023-2034) ($MN)
  • Table 102 South America Endocrine Testing Market Outlook, By Test Type (2023-2034) ($MN)
  • Table 103 South America Endocrine Testing Market Outlook, By Human Chorionic Gonadotropin Hormone Test (2023-2034) ($MN)
  • Table 104 South America Endocrine Testing Market Outlook, By Prolactin Test (2023-2034) ($MN)
  • Table 105 South America Endocrine Testing Market Outlook, By Progesterone Test (2023-2034) ($MN)
  • Table 106 South America Endocrine Testing Market Outlook, By Insulin Test (2023-2034) ($MN)
  • Table 107 South America Endocrine Testing Market Outlook, By Thyroid Stimulating Hormone Test (2023-2034) ($MN)
  • Table 108 South America Endocrine Testing Market Outlook, By Luteinizing Hormone Test (2023-2034) ($MN)
  • Table 109 South America Endocrine Testing Market Outlook, By Dehydroepiandrosterone Sulfate Test (2023-2034) ($MN)
  • Table 110 South America Endocrine Testing Market Outlook, By Estradiol Test (2023-2034) ($MN)
  • Table 111 South America Endocrine Testing Market Outlook, By Cortisol Test (2023-2034) ($MN)
  • Table 112 South America Endocrine Testing Market Outlook, By Testosterone Test (2023-2034) ($MN)
  • Table 113 South America Endocrine Testing Market Outlook, By Follicle Stimulating Hormone Test (2023-2034) ($MN)
  • Table 114 South America Endocrine Testing Market Outlook, By Other Test Types (2023-2034) ($MN)
  • Table 115 South America Endocrine Testing Market Outlook, By Technology (2023-2034) ($MN)
  • Table 116 South America Endocrine Testing Market Outlook, By Nucleic Acid Based (2023-2034) ($MN)
  • Table 117 South America Endocrine Testing Market Outlook, By Mass Spectroscopy (2023-2034) ($MN)
  • Table 118 South America Endocrine Testing Market Outlook, By Chromatography (2023-2034) ($MN)
  • Table 119 South America Endocrine Testing Market Outlook, By Immunoassay (2023-2034) ($MN)
  • Table 120 South America Endocrine Testing Market Outlook, By Other Technologies (2023-2034) ($MN)
  • Table 121 South America Endocrine Testing Market Outlook, By End User (2023-2034) ($MN)
  • Table 122 South America Endocrine Testing Market Outlook, By Clinical Laboratories (2023-2034) ($MN)
  • Table 123 South America Endocrine Testing Market Outlook, By Diagnostic Centers (2023-2034) ($MN)
  • Table 124 South America Endocrine Testing Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 125 South America Endocrine Testing Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 126 Middle East & Africa Endocrine Testing Market Outlook, By Country (2023-2034) ($MN)
  • Table 127 Middle East & Africa Endocrine Testing Market Outlook, By Test Type (2023-2034) ($MN)
  • Table 128 Middle East & Africa Endocrine Testing Market Outlook, By Human Chorionic Gonadotropin Hormone Test (2023-2034) ($MN)
  • Table 129 Middle East & Africa Endocrine Testing Market Outlook, By Prolactin Test (2023-2034) ($MN)
  • Table 130 Middle East & Africa Endocrine Testing Market Outlook, By Progesterone Test (2023-2034) ($MN)
  • Table 131 Middle East & Africa Endocrine Testing Market Outlook, By Insulin Test (2023-2034) ($MN)
  • Table 132 Middle East & Africa Endocrine Testing Market Outlook, By Thyroid Stimulating Hormone Test (2023-2034) ($MN)
  • Table 133 Middle East & Africa Endocrine Testing Market Outlook, By Luteinizing Hormone Test (2023-2034) ($MN)
  • Table 134 Middle East & Africa Endocrine Testing Market Outlook, By Dehydroepiandrosterone Sulfate Test (2023-2034) ($MN)
  • Table 135 Middle East & Africa Endocrine Testing Market Outlook, By Estradiol Test (2023-2034) ($MN)
  • Table 136 Middle East & Africa Endocrine Testing Market Outlook, By Cortisol Test (2023-2034) ($MN)
  • Table 137 Middle East & Africa Endocrine Testing Market Outlook, By Testosterone Test (2023-2034) ($MN)
  • Table 138 Middle East & Africa Endocrine Testing Market Outlook, By Follicle Stimulating Hormone Test (2023-2034) ($MN)
  • Table 139 Middle East & Africa Endocrine Testing Market Outlook, By Other Test Types (2023-2034) ($MN)
  • Table 140 Middle East & Africa Endocrine Testing Market Outlook, By Technology (2023-2034) ($MN)
  • Table 141 Middle East & Africa Endocrine Testing Market Outlook, By Nucleic Acid Based (2023-2034) ($MN)
  • Table 142 Middle East & Africa Endocrine Testing Market Outlook, By Mass Spectroscopy (2023-2034) ($MN)
  • Table 143 Middle East & Africa Endocrine Testing Market Outlook, By Chromatography (2023-2034) ($MN)
  • Table 144 Middle East & Africa Endocrine Testing Market Outlook, By Immunoassay (2023-2034) ($MN)
  • Table 145 Middle East & Africa Endocrine Testing Market Outlook, By Other Technologies (2023-2034) ($MN)
  • Table 146 Middle East & Africa Endocrine Testing Market Outlook, By End User (2023-2034) ($MN)
  • Table 147 Middle East & Africa Endocrine Testing Market Outlook, By Clinical Laboratories (2023-2034) ($MN)
  • Table 148 Middle East & Africa Endocrine Testing Market Outlook, By Diagnostic Centers (2023-2034) ($MN)
  • Table 149 Middle East & Africa Endocrine Testing Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 150 Middle East & Africa Endocrine Testing Market Outlook, By Other End Users (2023-2034) ($MN)